Literature DB >> 11518469

Expression of heparin-binding epidermal growth factor-like growth factor in breast carcinoma.

Y Ito1, T Takeda, S Higashiyama, S Noguchi, N Matsuura.   

Abstract

The expression of heparin-binding epidermal growth factor-like growth factor (HB-EGF) was investigated for 76 cases of breast carcinoma. HB-EGF was expressed in 71.8% of the carcinoma cases but only slightly in normal mammary glands. Interestingly, its expression was inversely related to biological aggressiveness of the breast carcinoma. These results suggest that HB-EGF may play a crucial role in the early stage of this carcinoma.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11518469     DOI： 10.1023/a:1010667108371

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN： 0167-6806            Impact factor:   4.872


  8 in total

1.  First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors.

Authors:  Kathleen N Moore; Johanna C Bendell; Patricia M LoRusso; Anthony J Olszanski; Esther Zwick-Wallasch; Mendel Jansen; Alexander G Vandell; Giorgio Senaldi
Journal:  Invest New Drugs       Date:  2018-07-28       Impact factor: 3.850

2.  Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.

Authors:  Suguru Dateoka; Yuichi Ohnishi; Kenji Kakudo
Journal:  Med Mol Morphol       Date:  2012-06-21       Impact factor: 2.309

3.  Gene expression profiling reveals that the regulation of estrogen-responsive element-independent genes by 17 beta-estradiol-estrogen receptor beta is uncoupled from the induction of phenotypic changes in cell models.

Authors:  Xiaodong Li; Stephanie L Nott; Yanfang Huang; Russell Hilf; Robert A Bambara; Xing Qiu; Andrei Yakovlev; Stephen Welle; Mesut Muyan
Journal:  J Mol Endocrinol       Date:  2008-05       Impact factor: 5.098

4.  Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer.

Authors:  John Sarantopoulos; Monica M Mita; Michael J Birrer; Lee D Cranmer; Luis T Campos; Xiaoping Zhang; Penelope Bristow; Hidekuni Kaito; Vincent Strout; Luis H Camacho
Journal:  Target Oncol       Date:  2016-06       Impact factor: 4.493

5.  Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression.

Authors:  Yi Zhang; Rachel M Gonzalez; Richard C Zangar
Journal:  BMC Cancer       Date:  2011-02-14       Impact factor: 4.430

6.  Identification of the potential crucial genes in invasive ductal carcinoma using bioinformatics analysis.

Authors:  Chunguang Li; Liangtao Luo; Sheng Wei; Xiongbiao Wang
Journal:  Oncotarget       Date:  2017-12-13

7.  Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator.

Authors:  Philip Vlaicu; Philipp Mertins; Thomas Mayr; Peter Widschwendter; Beyhan Ataseven; Bernhard Högel; Wolfgang Eiermann; Pjotr Knyazev; Axel Ullrich
Journal:  BMC Cancer       Date:  2013-04-18       Impact factor: 4.430

8.  Characterization of a Novel Anti-Human HB-EGF Monoclonal Antibody Applicable for Paraffin-Embedded Tissues and Diagnosis of HB-EGF-Related Cancers.

Authors:  Ryo Iwamoto; Mika Takagi; Jun-Ichi Akatsuka; Ken-Ichiro Ono; Yoshiro Kishi; Eisuke Mekada
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2016-03-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.